Cite
HARVARD Citation
Calza, L. et al. (2020). No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up. Infectious diseases. 52 (4), pp. 249-256. [Online].